These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 36322088)

  • 1. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
    Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
    Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
    Jin L; Zhang Y; Yang W
    Int J Gynaecol Obstet; 2020 Jun; 149(3):303-308. PubMed ID: 32133643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Exercise on Taxane Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer: A Randomized Controlled Trial.
    Bland KA; Kirkham AA; Bovard J; Shenkier T; Zucker D; McKenzie DC; Davis MK; Gelmon KA; Campbell KL
    Clin Breast Cancer; 2019 Dec; 19(6):411-422. PubMed ID: 31601479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial.
    Shimozuma K; Ohashi Y; Takeuchi A; Aranishi T; Morita S; Kuroi K; Ohsumi S; Makino H; Katsumata N; Kuranami M; Suemasu K; Watanabe T; Hausheer FH
    Support Care Cancer; 2012 Dec; 20(12):3355-64. PubMed ID: 22584733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
    Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
    JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population.
    Greenwald MK; Ruterbusch JJ; Beebe-Dimmer JL; Simon MS; Albrecht TL; Schwartz AG
    Cancer; 2019 Jan; 125(2):269-277. PubMed ID: 30387871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of taxane chemotherapy-induced nail changes and peripheral neuropathy by application of extremity cooling: a prospective single-centre study with intrapatient comparison.
    Johnson K; Stoffel B; Schwitter M; Hayoz S; Rojas Mora A; Fischer Maranta A; El Saadany T; Hasler U; von Moos R; Patzen A; Mark M; Roberts G; Cathomas R
    Support Care Cancer; 2024 Jul; 32(8):554. PubMed ID: 39066890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Genetic Polymorphism with Taxane-induced Peripheral Neuropathy: Sub-analysis of a Randomized Phase II Study to Determine the Optimal Dose of 3-week Cycle Nab-Paclitaxel in Metastatic Breast Cancer Patients.
    Abe Y; Taira N; Kashiwabara K; Tsurutani J; Kitada M; Takahashi M; Kato H; Kikawa Y; Sakata E; Naito Y; Hasegawa Y; Saito T; Iwasa T; Takashima T; Aihara T; Mukai H; Hara F; Shien T; Doihara H; Toyooka S
    Acta Med Okayama; 2022 Dec; 76(6):661-671. PubMed ID: 36549768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
    Sodhi M; Yeung SN; Maberley D; Mikelberg F; Etminan M
    JAMA Ophthalmol; 2022 Sep; 140(9):880-884. PubMed ID: 35951320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.
    Kida K; Yamada A; Shimada K; Narui K; Sugae S; Shimizu D; Doi T; Oba M; Endo I; Ishikawa T
    Breast Cancer; 2024 May; 31(3):409-416. PubMed ID: 38453739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Tolerability of Nab-paclitaxel in Younger versus Elderly Patients With Metastatic HR-positive/HER2-negative Breast Cancer: Results From the Noninterventional, Prospective Study NABUCCO.
    Potthoff K; Stötzer O; Söling U; Hansen R; Harde J; Dille S; Nusch A; Marschner N
    Clin Breast Cancer; 2020 Jun; 20(3):e315-e326. PubMed ID: 32273207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial using surgical gloves to prevent chemotherapy-induced peripheral neuropathy by paclitaxel in breast cancer patients (AIUR trial).
    Kang YJ; Yoon CI; Yang YJ; Baek JM; Kim YS; Jeon YW; Rhu J; Yi JP; Kim D; Oh SJ
    BMC Cancer; 2023 Jun; 23(1):570. PubMed ID: 37340369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
    Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
    BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
    Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
    Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
    Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
    Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.
    Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB
    JAMA Netw Open; 2024 Aug; 7(8):e2424139. PubMed ID: 39120903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients.
    Speck RM; DeMichele A; Farrar JT; Hennessy S; Mao JJ; Stineman MG; Barg FK
    Support Care Cancer; 2012 Oct; 20(10):2433-9. PubMed ID: 22231480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
    Chen CS; Smith EML; Stringer KA; Henry NL; Hertz DL
    Breast Cancer Res Treat; 2022 Aug; 194(3):551-560. PubMed ID: 35760975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.